Brief: BeyondSpring Says Co's Chinese Unit Withdrew NDA Submission
14/03/2023 12:40
March 14 (Reuters) - BeyondSpring Inc BYSI.O :
* BEYONDSPRING - CO'S CHINESE UNIT WITHDREW NDA SUBMISSION
OF
INDICATION OF PLINABULIN IN COMBINATION OF PEGFILGRASTIM AGENTS
FROM CHINA NMPA
* BEYONDSPRING INC - CO WILL CONTINUE TO COMMUNICATE WITH
NMPA
REGARDING RE-FILING OF CIN INDICATION
* BEYONDSPRING INC - CO WILL SUBMIT APPLICATION AS SOON AS
PRACTICALLY POSSIBLE
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value